84 related articles for article (PubMed ID: 8397255)
1. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.
Tilg H; Shapiro L; Atkins MB; Dinarello CA; Mier JW
J Immunol; 1993 Sep; 151(6):3299-307. PubMed ID: 8397255
[TBL] [Abstract][Full Text] [Related]
2. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
Tilg H; Shapiro L; Vannier E; Poutsiaka DD; Trehu E; Atkins MB; Dinarello CA; Mier JW
J Immunol; 1994 Mar; 152(6):3189-98. PubMed ID: 8144913
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans.
Bargetzi MJ; Lantz M; Smith CG; Torti FM; Olsson I; Eisenberg SP; Starnes HF
Cancer Res; 1993 Sep; 53(17):4010-3. PubMed ID: 8395334
[TBL] [Abstract][Full Text] [Related]
4. Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy.
Tilg H; Atkins MB; Dinarello CA; Mier JW
Cytokine; 1995 Oct; 7(7):734-9. PubMed ID: 8580384
[TBL] [Abstract][Full Text] [Related]
5. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
[TBL] [Abstract][Full Text] [Related]
9. In vitro anti-inflammatory activity of Phlebodium decumanum. Modulation of tumor necrosis factor and soluble TNF receptors.
Punzón C; Alcaide A; Fresno M
Int Immunopharmacol; 2003 Sep; 3(9):1293-9. PubMed ID: 12890427
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
[TBL] [Abstract][Full Text] [Related]
11. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer.
Kopp WC; Urba WJ; Rager HC; Alvord WG; Oppenheim JJ; Smith JW; Longo DL
Clin Cancer Res; 1996 Mar; 2(3):501-6. PubMed ID: 9816196
[TBL] [Abstract][Full Text] [Related]
12. Synergetic effect of dialyzer membrane and lipopolysaccharide on peripheral blood mononuclear cell cytokine production in uremic patients.
Gu Y; Ding F; Qin H; Zhao H; Lin S
Chin Med J (Engl); 2000 Apr; 113(4):315-9. PubMed ID: 11775226
[TBL] [Abstract][Full Text] [Related]
13. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes.
Malyak M; Smith MF; Abel AA; Hance KR; Arend WP
J Immunol; 1998 Aug; 161(4):2004-10. PubMed ID: 9712073
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production.
Tsuboi I; Tanaka H; Nakao M; Shichijo S; Itoh K
Cytokine; 1995 May; 7(4):372-9. PubMed ID: 8589268
[TBL] [Abstract][Full Text] [Related]
15. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia.
Calkins CM; Bensard DD; Shames BD; Pulido EJ; Abraham E; Fernandez N; Meng X; Dinarello CA; McIntyre RC
J Endotoxin Res; 2002; 8(1):59-67. PubMed ID: 11981446
[TBL] [Abstract][Full Text] [Related]
16. Relative cytokine and cytokine inhibitor production by mononuclear cells and neutrophils.
Xing L; Remick DG
Shock; 2003 Jul; 20(1):10-6. PubMed ID: 12813362
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo.
McKenzie RC; Oran A; Dinarello CA; Sauder DN
Anticancer Res; 1996; 16(1):437-41. PubMed ID: 8615650
[TBL] [Abstract][Full Text] [Related]
18. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns.
Endo S; Inada K; Yamada Y; Kasai T; Takakuwa T; Nakae H; Kamei Y; Shimamura T; Suzuki T; Taniguchi S; Yoshida M
J Med; 1996; 27(1-2):57-71. PubMed ID: 8863178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
